Drug intelligence / Profile preview

STAT-205

Development stage: Phase 1
Lead developer: Statera BioPharma
Modality: Small Molecules
Administration: Oral

Overview

STAT-205 is an investigational small molecule immunomodulator developed for the potential treatment of acute and post-acute (long-haul) COVID infections. It is designed to modulate immune system function, specifically by decreasing elevated inflammatory responses associated with SARS-CoV-2 viral infections. The drug acts as an oral immunomodulator, targeting cytokine production and modulating Th1/Th2 helper cell balance to control immune dysfunction. Preliminary in vitro data suggest it may slow or halt SARS-CoV-2 progression in human lung cells[1][3][4].

Targets

TLR (Toll-like receptors)IL10 (Interleukin-10)

Beyond the preview

Go deeper on STAT-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAT-205.